Sitravatinib
Phase 3Small molecule
Sitravatinib is an experimental drug being studied to treat certain types of cancer, particularly those with specific genetic mutations that make cancer cells grow.[1] Sitravatinib is currently being investigated across 15 indications[3], with its most advanced program in Phase 3.[1]
Sitravatinib is one of 429 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.
15
Indications
31
Total Trials
3
Active Trials
428
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 15 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Sitravatinib
MMirati Therapeutics Inc.
Phase 3
Trodelvy
GileadPreclinical
Tykerb
GSKPreclinical
Tecentriq
RochePreclinical
Halaven
EisaiPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer4 trials
Hepatocellular Carcinoma2 trials
Breast Cancer2 trials
Renal Cell Carcinoma2 trials
19 more indications
Oral Cavity Cancer1 trial
Metastatic Melanoma1 trial
Esophageal Squamous Cell Carcinoma1 trial
Endometrial Cancer1 trial
Biliary Tract Cancer1 trial
Locally Advanced1 trial
Urothelial Carcinoma1 trial
Adult1 trial
Advanced Malignancies1 trial
Cancer1 trial
Hepatic Impairment1 trial
Cervical Cancer1 trial
Maintenance Therapy1 trial
Non-squamous NSCLC1 trial
Kidney Cancer1 trial
Advanced Solid Tumors1 trial
Renal Cell Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sitravatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMirati Therapeutics Inc.